期刊
CURRENT OPINION IN GASTROENTEROLOGY
卷 30, 期 3, 页码 279-286出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOG.0000000000000056
关键词
fibrate; multidrug resistance protein 3; peroxisome proliferator activated receptor; primary biliary cirrhosis; ursodeoxycholic acid
资金
- Austrian Science Fund (FWF) project 'Transmembrane Transporters in Health and Disease' [F3517]
- EASL Dame Sheila Sherlock short-term fellowship
- Falk Phrama
- Phenex
- Falk Pharma
- Intercept
- MSD
- Falk Foundation
- Gilead
- Roche
Purpose of reviewPrimary biliary cirrhosis (PBC) can lead to end-stage liver disease and death. Ursodeoxycholic acid (UDCA) treatment can normalize serum liver enzymes in PBC, and such UDCA-responsive patients have a similar life expectancy as age and sex-matched controls. Nearly up to 50% of the patients with PBC, depending on sex and age at diagnosis, show an incomplete biochemical response to UDCA and require additional/alternative treatment. The purpose of this review is to critically evaluate the molecular mechanisms and clinical benefit of fibrate treatment in these patients.Recent findingsFibrates have anticholestatic, anti-inflammatory, and antifibrotic effects in animal and in-vitro studies. The mechanisms that underlie these effects are complementary, and largely mediated through activation of peroxisome proliferator activated receptors. Fibrate treatment ameliorated liver biochemical tests in UDCA unresponsive patients, either as mono-therapy or in combination with UDCA. These results, however, were obtained in case series and small pilot studies. The results of phase III studies, such as the Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (BEZURSO) trial, are currently awaited.SummaryA considerable body of observational evidence supports the safety and efficacy of fibrate treatment in PBC patients with an incomplete response to UDCA. These results encourage the evaluation of its effects on liver-related morbidity and mortality in larger clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据